AGP Executive Report
Last update: 8 hours agoCancer Drug Advances: RYZ101 met its Phase 3 progression-free survival endpoint in advanced gastroenteropancreatic neuroendocrine tumors, offering a potential new option after lutetium-based treatment. Surgical Robotics: Stryker is investing about $400 million in CMR Surgical and will exclusively distribute its soft-tissue surgical robot in the U.S. Imaging Strategy: Siemens Healthineers has stopped selling general ultrasound systems as it shifts toward cardiovascular and image-guided procedures. Patient Safety: Lilly is warning consumers about illegal sales of its investigational obesity drug retatrutide, which has not been approved and may pose risks from poor-quality products, dosing and inadequate monitoring. Workforce Wellbeing: A comparison of doctors in the UK and Australia finds shared pressures—including heavy workloads and training strain—pointing to workplace systems, not individual resilience alone, as a key concern.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
